Metagenomi Therapeutics, Inc. (MGX) Return on equity 2024–2025
Metagenomi Therapeutics, Inc. (MGX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-55.4%FY2025 · since FY2024: -33.2% → -55.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -55.4% | -22.2 pp |
| FY2024 | -33.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice